# Sun Pharmaceuticals Ltd. appears to be confident about its acquisition of Organon.

*business · news · 2026-04-27 · NDTV Profit*

## Key points

- Sun Pharma projects $350 million in cost synergies from the Organon acquisition over 2–4 years.
- The Organon acquisition will be financed with $2–2.5 billion from Sun Pharma’s surplus and $9.25–9.75 billion in external borrowing.
- Combined entities are currently generating $2.5 billion in cash, expected to grow post-acquisition.
- The acquisition, valued at $11.75 billion, is expected to complete in early 2027 pending approvals.

**Companies:** Sun Pharmaceuticals Ltd., Organon
**Countries:** India, United States

[Read the full story on NDTV Profit](https://www.ndtvprofit.com/business/sun-pharma-expects-organon-acquisition-to-boost-margins-unlock-cost-synergies-worth-350-million-11415606)

---

Canonical: https://newsio.io/n/c1a022f6-d0a9-4438-8ac6-1a7229247ebe/sun-pharmaceuticals-ltd-appears-to-be-confident-about-its-acquisition-of-organon
Summarized by Newsio from NDTV Profit. https://newsio.io/how-it-works